SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Xiaoping Zhang who wrote (100)7/2/1998 11:15:00 AM
From: Harold V  Read Replies (1) | Respond to of 192
 
Xiaoping, thanks for sharing your research with us and for alerting us to the reasons why MRE's EPS may fall off some in the future. I agree with all the points you make as to why MRE is undervalued. If their EPS declines in the 3rd quarter and beyond, we will probably be looking at a buying opportunity. Then again, the off-label use and expanding cardiac testing use of Adenosine have be such that earning surprises continue. I'm thinking of selling some shares after the release of quarterly earnings in the middle of this month in hopes of buying back in later. But at the moment, I'm keeping my options open. Thanks again for your digging. Harold V



To: Xiaoping Zhang who wrote (100)7/23/1998 8:22:00 PM
From: Xiaoping Zhang  Read Replies (1) | Respond to of 192
 
Re: Update on Tax Rate.

I received an E-mail yesterday from the company, updating me on the tax rate issue. The company said that, after discussion with tax consultants, it was expected that, due to the tax credits, NOL, etc., the company would not pay full tax rate until 1999.

X.Z.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News